Latest Breaking News On - Longest studied - Page 1 : comparemela.com

/PRNewswire/ Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER.

Puerto ricoUnited statesMichael strapazonJessica akopyanAmgen medinfoKyowa kirin co ltdBeigene ltdExchange commissionTherapeutics incEuropean unionTeneobio incStudies showed sustained reductionCombined studies evaluated safetyMore thanOver five years after completingLongest studied